NCT01568866 (ENDEAVOR) Clinical Trial

Study Title

Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients (ENDEAVOR) (NCT01568866)

Trial Description

The primary objective of this study was to compare progression-free survival in patients with multiple myeloma who relapsed after 1 to 3 prior therapies treated with carfilzomib plus dexamethasone or bortezomib plus dexamethasone.

This trial is sponsored by?Amgen?

Study Data

  • Condition:?Relapsed Multiple Myeloma
  • Interventions:
    • Drugs used in this trial
      • Carfilzomib
      • Bortezomib
      • Dexamethasone
  • Phase:?III
  • Enrollment: 929
  • Start:?June 2012
  • Estimated Completion:?December 2018
  • Last verified:
  • Last Updated:

Study Schematic

Click here to Return to Drug map

Last Editorial review: August 24, 2017
Information based on (NIH/NCI) and other sources.

Copyright ? 2015-2017 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.